文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

实体器官移植重症患者临时停用慢性免疫抑制药物对第90天死亡率和ICU获得性感染的影响:一项回顾性多中心研究

Effect of temporary suspension of chronic immunosuppressive drugs on day-90 mortality and ICU-acquired infections among critically Ill patients with solid organ transplant: a retrospective multicenter study.
PubMed 文献 · Intensive Care Med · 2025-07-16
一句话结论实体器官移植ICU患者临时停用免疫抑制药物>24小时可能降低ICU获得性感染风险(贝叶斯分析73%获益概率),但对第90天死亡率影响不确定。

这项在9个ICU开展的多中心回顾性观察研究纳入591例实体器官移植患者,采用基于专家小组信念启发过程的贝叶斯先验分析。34%的患者采用了临时停用免疫抑制药物策略,中位停用5天(IQR 3-10天),该策略在脓毒症(38%)或COVID-19(49%)入院患者中比非脓毒症原因(24%)更常见(p<0.001)。总体第90天死亡率为30%,贝叶斯分析显示OR 1.13(95%CrI 0.74-1.70),获益概率15%;脓毒症亚组OR 0.90(95%CrI 0.55-1.55),获益概率50%。ICU获得性感染发生率为26%,停用策略在全队列显示潜在获益(获益概率73%,OR 0.74,95%CrI 0.49-1.15),脓毒症亚组获益概率78%(OR 0.70,95%CrI 0.42-1.16)。作者认为临时停用免疫抑制药物可能降低ICU获得性感染风险,但对第90天死亡率存在真实不确定性,需前瞻性研究证实。

要点

  • 在591例实体器官移植ICU患者中,34%采用了临时停用免疫抑制药物>24小时策略,中位停用5天(IQR 3-10)。
  • 停用策略在脓毒症入院(38%)或COVID-19入院(49%)患者中比非脓毒症原因(24%)更常见(p<0.001)。
  • 总体第90天死亡率为30%,停用策略与死亡率关联的OR为1.13(95%CrI 0.74-1.70),获益概率仅15%。
  • ICU获得性感染发生率为26%,停用策略在全队列的OR为0.74(95%CrI 0.49-1.15),获益概率73%。
  • 脓毒症亚组中停用策略的OR为0.70(95%CrI 0.42-1.16),获益概率78%,但置信区间均跨1。

适用人群与场景

  • 9个ICU收治的实体器官移植患者,共591例。
  • 按入院原因分层:脓毒症、COVID-19、非脓毒症原因。

诊断标准与关键阈值

  • 临时停用策略定义为中断免疫抑制药物>24小时。

研究设计与关键结果

  • 研究类型:多中心回顾性观察研究,纳入9个ICU的实体器官移植患者591例,采用基于专家小组信念启发过程的贝叶斯先验分析。
  • 停用策略使用率34%,中位停用5天(IQR 3-10天);脓毒症入院38%、COVID-19入院49%、非脓毒症原因24%(p<0.001)。
  • 总体第90天死亡率30%;停用策略与死亡率关联OR 1.13(95%CrI 0.74-1.70),获益概率15%;脓毒症亚组OR 0.90(95%CrI 0.55-1.55),获益概率50%。
  • ICU获得性感染发生率26%;停用策略全队列OR 0.74(95%CrI 0.49-1.15),获益概率73%;脓毒症亚组OR 0.70(95%CrI 0.42-1.16),获益概率78%。

证据类型、等级与局限

  • 证据类型:多中心回顾性观察研究,采用贝叶斯分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为临时停用免疫抑制药物可能降低ICU获得性感染风险,但对第90天死亡率存在真实不确定性。
  • 作者建议需前瞻性研究证实这些结果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Decision-making for management of immunosuppressive drugs in solid organ transplant patients admitted to the ICU remains controversial. This study aimed to evaluate the impact of a temporary suspension strategy (interruption of immunosuppressive drugs > 24h) on day-90 mortality and ICU-acquired infections.

METHODS: This multicenter observational retrospective study conducted in solid organ transplant patients admitted to nine ICUs used a Bayesian approach with priors based on a belief elicitation process conducted among a panel of experts.

RESULTS: Among 591 enrolled patients, suspension strategy was used in 34% of them, during a median period of 5 days [IQR: 3-10]. This approach was more common in patients admitted for sepsis (38%) or COVID-19 (49%) than for non-septic causes (24%) (p < 0.001). Overall, day-90 mortality reached 30%, and Bayesian analysis revealed substantial uncertainty with an OR at 1.13 (95% Credible Interval (CrI): 0.74-1.70), and a 15% probability of a beneficial effect. In the subgroup of patients with sepsis, OR was at 0.90 (95% CrI: 0.55-1.55), with a 50% probability of a beneficial effect. ICU-acquired infections occurred in 26% of patients. The suspension strategy indicated a potential benefit, both in the entire cohort, with a 73% probability of a beneficial effect [OR: 0.74 (95% CrI: 0.49-1.15)], and in the subgroup of sepsis patients with a 78% probability of beneficial effect [OR 0.70 (95% CrI, 0.42-1.16)].

CONCLUSION: Temporary suspension of immunosuppressive drugs may reduce the risk of ICU-acquired infections, with a true uncertainty on day-90 mortality. Prospective studies are warranted to confirm these results.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Vaidie J, Demiselle J, Gabriel A, et al. Effect of temporary suspension of chronic immunosuppressive drugs on day-90 mortality and ICU-acquired infections among critically Ill patients with solid organ transplant: a retrospective multicenter study. Intensive Care Med. 2025. PMID: 40668232. doi:10.1007/s00134-025-08024-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。